Sanpraz (Pantoprazole) pills

Sanpraz (Pantoprazole) pills

To favorites
Sanpraz (Pantoprazole) blocks the final stage of secretion of hydrochloric acid, reduces the level of secretion of hydrochloric acid in the stomach, proton pump lowering agent inhibitor
Active substance:Pantoprazole
Pharmacological group:GI tract and liver
Dosage mg:40
In stock
In stock
We deliver goods to almost any country. Each parcel is assigned a track number
You can pay by Paypal or any card Visa or Mastercard
Discount system
Cumulative discounts and Bonus program for our clients
Original goods
We offer our customers only original products

Always fresh Sanpraz (Pantoprazole) pills

English product name

Release form Sanpraz
T., intestinal-soluble shell, 40 mg: 10, 20 or 30 pcs

Description Sanpraz:

The tablets, which are covered with a yellow intestinal-soluble shell, are round and double-convex.

1 tab.
pantoprazole sodium sesquihydrate 45.1 mg,
which corresponds to pantoprazole content 40 mg
Auxiliary substances: magnesium oxide - 18 mg, calcium carbonate - 81.4 mg, crosbovidone - 35 mg, sodium lauryl sulfate - 5 mg, calcium stearate - 3 mg, silicon dioxide colloidal - 5 mg.

Shell Composition:
The copolymer of methacrylic acid and ethylacrylate (1:1) - 11 mg, triethyl citrate - 1.1 mg, copovidone - 7 mg, talc - 10.7 mg, titanium dioxide (E171) - 0.8 mg, iron oxide yellow (E172) - 0.2 mg, macrogol 6000 - 0.35 mg.

10 pcs - aluminium strips (1) - cardboard packs.
10 pcs - aluminum strips (2) - cardboard packs.
10 pcs - aluminium strips (3) - cardboard packs.

ATC codes
A02BC02 Pantoprazole

Clinical-pharmacological groups
Antiulcer preparation

Active substance

Pharmacotherapy group Sanpraz:

Proton pump inhibitor

Storage Conditions
The drug should be stored in a dry, protected from light and inaccessible to children at a temperature not higher than 25 ° C.

Best before date
Shelf life is 3 years.

Testimony Sanpraz:

stomach or duodenal ulcer disease in the exacerbation phase;
erosive gastritis (also associated with Helicobacter pylori);
Erosive ulcer lesions of the stomach and duodenum associated with NSAIDs;
reflux esophagitis.

Method of use, course and dosage Sanpraz:

In the case of gastric and duodenal ulcers, an erosive gastritis is prescribed at 40-80 mg/day. The course of treatment for the exacerbation of duodenal ulcer disease is two weeks, and gastric ulcer disease is four to eight weeks.

For the prophylaxis of exacerbations of gastric and duodenal ulcer, twenty mg/day is prescribed.
For the eradication of Helicobacter pylori take forty mg twice/day in combination with antimicrobial agents. The course of therapy is 7-14 days.
In the case of oral ulcerative lesions of the stomach and duodenum associated with NSAIDs, 40-80 mg/day is prescribed. The course of treatment is four to eight weeks. For the prophylaxis of erosive lesions against the background of long-term use of NSAIDs - twenty mg/day.
For reflux-esophagy, 20-40 mg/day is prescribed. The course of therapy is 4-8 weeks. For the prevention of exacerbations take twenty mg/day.
In patients with severe liver disorders, the dose should be reduced to 40 mg once every two days, and biochemical blood values should be monitored. When liver enzymes become more active, the drug should be discontinued.
The tablets are taken completely inside (without grinding or dissolving), having enough liquid. The drug is recommended to take 1 hour before breakfast, at a rate of twice a day the second dose - one before

Terms of Sale
The drug is prescription.

Use in children
Contraindication: Children's age (due to lack of data on the use of the drug in pediatric practice).

  • Nosology (ICD codes)
  • K21.0
  • Gastroesophageal reflux with esophagitis
  • K25
  • Stomach ulcer
  • K26
  • Duodenum ulcer
  • K27
  • Peptic ulcer
  • K29
  • Gastritis and duodenitis

Pharmacological effect Sanpraz:

H+-K+-ATP-ase inhibitor. It blocks the final stage of chlorohydrogen (hydrochloric) acid secretion, reduces basal and stimulated (regardless of the type of irritant) chlorohydrogen (hydrochloric) acid secretion in the stomach. In the case of duodenal ulcer, associated with Helicobacter pylori, reduced gastric secretion increases the sensitivity of microcosm to antibiotics.

Does not affect the motor of the gastrointestinal tract. The secretory activity normalizes three to four days after the end of the drug.

Active substance
Pharmacological group
Dosage mg
Country of origin
Expiration Date (in months)
No reviews yet — your comment may be first.
All reviews 0
general rating